Julie Earl1,2, Daniel Rico3, Enrique Carrillo-de-Santa-Pau4, Benjamín Rodríguez-Santiago5,6, Marinela Méndez-Pertuz7, Herbert Auer8, Gonzalo Gómez9, H Barton Grossman10, David G Pisano11, Wolfgang A Schulz12, Luis A Pérez-Jurado13,14, Alfredo Carrato15, Dan Theodorescu16, Stephen Chanock17, Alfonso Valencia18, Francisco X Real19,20. 1. Epithelial Carcinogenesis Group, F BBVA Cancer Cell Biology Programme, CNIO (Spanish National Cancer Research Centre), Melchor Fernández Almagro, 3, 28029, Madrid, Spain. jearl@ext.cnio.es. 2. Servicio de Oncología Médica, Hospital Ramón y Cajal, Madrid, Spain. jearl@ext.cnio.es. 3. Structural Computational Biology Group, Structural Biology and Biocomputing Programme, CNIO (Spanish National Cancer Research Centre), Madrid, Spain. drico@cnio.es. 4. Epithelial Carcinogenesis Group, F BBVA Cancer Cell Biology Programme, CNIO (Spanish National Cancer Research Centre), Melchor Fernández Almagro, 3, 28029, Madrid, Spain. ecarrillo@cnio.es. 5. Quantitative Genomic Medicine Laboratory, qGenomics, Barcelona, Spain. benjamin.rodriguez@qgenomics.com. 6. Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Barcelona, Spain. benjamin.rodriguez@qgenomics.com. 7. Epithelial Carcinogenesis Group, F BBVA Cancer Cell Biology Programme, CNIO (Spanish National Cancer Research Centre), Melchor Fernández Almagro, 3, 28029, Madrid, Spain. mmendez@cnio.es. 8. Institut de Recerca Biomèdica de Barcelona, Parc Científic de Barcelona, Barcelona, Spain. herbert.auer@irbbarcelona.org. 9. Bioinformatics Unit, Structural Biology and Biocomputing Programme, CNIO (Spanish National Cancer Research Centre), Madrid, Spain. ggomez@cnio.es. 10. Department of Urology, MD Anderson Cancer Center, Houston, TX, USA. hbgrossman@mdanderson.org. 11. Bioinformatics Unit, Structural Biology and Biocomputing Programme, CNIO (Spanish National Cancer Research Centre), Madrid, Spain. dgpisano@cnio.es. 12. Department of Urology, Heinrich-Heine-University, Düsseldorf, Germany. wolfgang.schulz@uni-duesseldorf.de. 13. Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain. luis.perez@upf.edu. 14. Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Barcelona, Spain. luis.perez@upf.edu. 15. Servicio de Oncología Médica, Hospital Ramón y Cajal, Madrid, Spain. acarrato@telefonica.net. 16. University of Colorado Comprehensive Cancer Center, Aurora, CO, 80045, USA. dan.theodorescu@ucdenver.edu. 17. Translational Genomics Laboratory, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, USA. chanocks@mail.nih.gov. 18. Structural Computational Biology Group, Structural Biology and Biocomputing Programme, CNIO (Spanish National Cancer Research Centre), Madrid, Spain. avalencia@cnio.es. 19. Epithelial Carcinogenesis Group, F BBVA Cancer Cell Biology Programme, CNIO (Spanish National Cancer Research Centre), Melchor Fernández Almagro, 3, 28029, Madrid, Spain. preal@cnio.es. 20. Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain. preal@cnio.es.
Following the publication of our recent article in BMC Genomics [1] a number of aspects were called to our attention. We have carefully reviewed the experiments reported in this manuscript, as well as additional data from our laboratories, and would like to make the following points:SW-850, included in our paper as a bladder cancer cell line, has been reported by several authors to be a pancreatic cancer cell line [2-5]. This is unlikely to be the case given that most pancreatic cancers are KRAS-mutant and both our analysis and a previous publication [5] indicate that the cells used are KRAS-wild type. However, given the controversy we recommend that these cells are not be used as bladder cancer models.The Materials and Methods section of our paper indicated that the following cell lines were obtained from ATCC: 253 J, 575A, 639 V, JON, MGH-U4, SW-800, SW-1710, VM-CUB-2. However, these cultures have never been distributed by the ATCC. Therefore, they are available from us if other investigators are interested in using them.It has been reported that UM-UC-2 is a T24 contaminant (http://www.ncbi.nlm.nih.gov/biosample/SAMN03151953 ,http://web.expasy.org/cellosaurus/CVCL_8155, http://iclac.org/wp-content/uploads/Cross-Contaminations-v7_2.pdf). We have used fingerprinting analysis to confirm this fact and the genetic identity of the cells/DNAs used in our experiments (Table 1).
Table 1
SNP fingerprint analysis of the bladder cancer cell lines suffering from an “identity crisis”
Cell Line
Comments
D5S818
D13S317
D7S820
D16S539
VWA
TH01
AM
TPOX
CSF1PO
VM- CUB-1 p29
11
10
8,11
11,12
18,19
9
X
8
11
VM-CUB-2 p112
11,13
12
8
9
14
7
X,Y
8,12
11,12
VM-CUB-3 p65
11
9,12
8,9
12
16
9.3
X
8
12
UM-UC-2 p264
DNA fingerprinting data, same as T24
10,12
10,12
10,11
9
17
6
X
8,11
10,12
T24 p8
ATCC
10,12
12
10,11
9
17,19
6
X
8,11
10,12
P passage
It has been reported that VM-CUB-3 is a VM-CUB-1 contaminant (http://iclac.org/wp-content/uploads/Cross-Contaminations-v7_2.pdf, http://www.ncbi.nlm.nih.gov/biosample/3152040, http://web.expasy.org/cellosaurus/CVCL_9830). Nevertheless, our data indicate that the two cultures we used as VM-CUB-1 and VM-CUB-3 are distinct at the genomic level. Furthermore, as shown in Table 1, fingerprinting analysis clearly indicates that VM-CUB-1, VM-CUB-2, and VM-CUB-3 are different from each other. The origin of the DNA/cells in our paper was as indicated in the Material and Methods section and, therefore, investigators interested in these cells could directly address the corresponding co-authors.SNP fingerprint analysis of the bladder cancer cell lines suffering from an “identity crisis”P passageIn the last few years there has been much emphasis on the need to accurately designate, identify, and characterize cancer cell lines as they are precious tools for cell biology studies [6, 7]. It is with this aim that we wish to make these comments and clarifications related to our recently published work.
Authors: Mamie Yu; Suresh K Selvaraj; May M Y Liang-Chu; Sahar Aghajani; Matthew Busse; Jean Yuan; Genee Lee; Franklin Peale; Christiaan Klijn; Richard Bourgon; Joshua S Kaminker; Richard M Neve Journal: Nature Date: 2015-04-16 Impact factor: 49.962
Authors: Leonard P Freedman; Mark C Gibson; Stephen P Ethier; Howard R Soule; Richard M Neve; Yvonne A Reid Journal: Nat Methods Date: 2015-06 Impact factor: 28.547
Authors: H Kalthoff; W Schmiegel; C Roeder; D Kasche; A Schmidt; G Lauer; H G Thiele; G Honold; K Pantel; G Riethmüller Journal: Oncogene Date: 1993-02 Impact factor: 9.867
Authors: Julie Earl; Daniel Rico; Enrique Carrillo-de-Santa-Pau; Benjamín Rodríguez-Santiago; Marinela Méndez-Pertuz; Herbert Auer; Gonzalo Gómez; Herbert Barton Grossman; David G Pisano; Wolfgang A Schulz; Luis A Pérez-Jurado; Alfredo Carrato; Dan Theodorescu; Stephen Chanock; Alfonso Valencia; Francisco X Real Journal: BMC Genomics Date: 2015-05-22 Impact factor: 3.969
Authors: Julie Earl; Daniel Rico; Enrique Carrillo-de-Santa-Pau; Benjamín Rodríguez-Santiago; Marinela Méndez-Pertuz; Herbert Auer; Gonzalo Gómez; H Barton Grossman; David G Pisano; Wolfgang A Schulz; Luis A Pérez-Jurado; Alfredo Carrato; Dan Theodorescu; Stephen Chanock; Alfonso Valencia; Francisco X Real Journal: BMC Genomics Date: 2016-10-25 Impact factor: 3.969